Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Institut Jules Bordet, Brussels

CHU Brugmann, Brussels

Cliniques Universitaires Saint-Luc, Brussels

Blacktown Cancer and Haematology Centre, Blacktown

Scientia Clinical Research, Randwick

Saint Augustinus Hospital, Antwerp

Austin Hospital, Heidelberg

Greenslopes Private Hospital, Brisbane

Mi Kryviy Rih Center of Dnipropetrovsk Regional Council, Charleroi

Linear Clinical Research, Perth

CHA Centre Hospitalier de l'Ardenne, Libramont

AZ Groeninge, Kortrijk

Memorial Sloan Kettering Cancer, New York

Hospital Reina Sophia, Córdoba

University of Pittsburgh, UPMC Cancer Pavilion, Pittsburgh

Fox Chase Cancer Center, Philadelphia

The University of North Carolina at Chapel Hill, Chapel Hill

University Hospital Ramon y Cajal, Madrid

Hospital Universitario Doce de Octubre, Madrid

Hospital HM Sanchinarro, Madrid

Clinica Universidad De Navarra (CUN), Pamplona

University of Florida, Gainesville

Washington University - Siteman Cancer Center, St Louis

Tennessee Oncology, Sarah Cannon Research Institute, Nashville

Ghent University Hospital, Ghent

Hospital Universitario Virgen Del Rocio, Seville

Karmanos Cancer Institute, Detroit

University of Oklahoma, Sarah Cannon Research Institute, Oklahoma City

BUMC Mary Crowley Cancer Research Centers, Dallas

MD Anderson, Houston

The Angeles Clinic and Research Institute, Los Angeles

Providance Portland Medical Center, Portland

Seattle Cancer Care Alliance, Seattle

Hackensack University Medical Center, Hackensack

Hospital Clinic I Provincial, Barcelona

Hospital Clinico y Provincial de Barcelona, Barcelona

Institut Catala D'Oncologia-Badalona, Barcelona

Hospital Vall de Hebron, Barcelona